Discrepancies Between Nomenclature and Indications of Psychotropics

Fusaka Minami, Joseph Zohar, Takefumi Suzuki, Teruki Koizumi, Masaru Mimura, Gohei Yagi, Hiroyuki Uchida

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introduction While the current nomenclature of psychotropic drugs is disease-based, their approved indications do not always match their classifications. Methods Information on approved indications of “second-generation antipsychotics” and “newer antidepressants” that are available in the United States (US), the United Kingdom (UK), France, Germany, and Japan were extracted from their packet inserts. Results A significant proportion of “atypical antipsychotics” were approved for psychiatric conditions other than psychotic disorders (i. e., bipolar disorder, major depressive disorder, and autistic disorder) as follows: 76.9% in the US, 66.7% in the UK, 66.7% in France, 60.0% in Germany, and 44.4% in Japan. Likewise, more than half of “newer antidepressants” had approved indications for psychiatric conditions other than depression (e. g., panic disorder, obsessive compulsive disorder, social anxiety disorder, general anxiety disorder, and post-traumatic stress disorder): 56.3% in the US, 69.2% in the UK, 69.2% in France, 50.0% in Germany, and 62.5% in Japan. Conclusions Our results raise concerns regarding generic terminologies of “antipsychotics” and “antidepressants” since the conventional indication-based nomenclature does not fit well with the official indication.

Original languageEnglish
JournalPharmacopsychiatry
DOIs
Publication statusAccepted/In press - 2018 May 23

Fingerprint

Terminology
Antidepressive Agents
Antipsychotic Agents
France
Germany
Japan
Psychiatry
Panic Disorder
Obsessive-Compulsive Disorder
Psychotropic Drugs
Major Depressive Disorder
Post-Traumatic Stress Disorders
Autistic Disorder
Anxiety Disorders
Bipolar Disorder
Psychotic Disorders
Depression
United Kingdom

Keywords

  • antidepressant
  • antipsychotic
  • indication
  • NbN
  • neuroscience-based nomenclature

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Discrepancies Between Nomenclature and Indications of Psychotropics. / Minami, Fusaka; Zohar, Joseph; Suzuki, Takefumi; Koizumi, Teruki; Mimura, Masaru; Yagi, Gohei; Uchida, Hiroyuki.

In: Pharmacopsychiatry, 23.05.2018.

Research output: Contribution to journalArticle

Minami, Fusaka ; Zohar, Joseph ; Suzuki, Takefumi ; Koizumi, Teruki ; Mimura, Masaru ; Yagi, Gohei ; Uchida, Hiroyuki. / Discrepancies Between Nomenclature and Indications of Psychotropics. In: Pharmacopsychiatry. 2018.
@article{74f8af69b52e41e093a88183bd62bcbc,
title = "Discrepancies Between Nomenclature and Indications of Psychotropics",
abstract = "Introduction While the current nomenclature of psychotropic drugs is disease-based, their approved indications do not always match their classifications. Methods Information on approved indications of “second-generation antipsychotics” and “newer antidepressants” that are available in the United States (US), the United Kingdom (UK), France, Germany, and Japan were extracted from their packet inserts. Results A significant proportion of “atypical antipsychotics” were approved for psychiatric conditions other than psychotic disorders (i. e., bipolar disorder, major depressive disorder, and autistic disorder) as follows: 76.9{\%} in the US, 66.7{\%} in the UK, 66.7{\%} in France, 60.0{\%} in Germany, and 44.4{\%} in Japan. Likewise, more than half of “newer antidepressants” had approved indications for psychiatric conditions other than depression (e. g., panic disorder, obsessive compulsive disorder, social anxiety disorder, general anxiety disorder, and post-traumatic stress disorder): 56.3{\%} in the US, 69.2{\%} in the UK, 69.2{\%} in France, 50.0{\%} in Germany, and 62.5{\%} in Japan. Conclusions Our results raise concerns regarding generic terminologies of “antipsychotics” and “antidepressants” since the conventional indication-based nomenclature does not fit well with the official indication.",
keywords = "antidepressant, antipsychotic, indication, NbN, neuroscience-based nomenclature",
author = "Fusaka Minami and Joseph Zohar and Takefumi Suzuki and Teruki Koizumi and Masaru Mimura and Gohei Yagi and Hiroyuki Uchida",
year = "2018",
month = "5",
day = "23",
doi = "10.1055/a-0626-7135",
language = "English",
journal = "Pharmacopsychiatry",
issn = "0176-3679",
publisher = "Georg Thieme Verlag",

}

TY - JOUR

T1 - Discrepancies Between Nomenclature and Indications of Psychotropics

AU - Minami, Fusaka

AU - Zohar, Joseph

AU - Suzuki, Takefumi

AU - Koizumi, Teruki

AU - Mimura, Masaru

AU - Yagi, Gohei

AU - Uchida, Hiroyuki

PY - 2018/5/23

Y1 - 2018/5/23

N2 - Introduction While the current nomenclature of psychotropic drugs is disease-based, their approved indications do not always match their classifications. Methods Information on approved indications of “second-generation antipsychotics” and “newer antidepressants” that are available in the United States (US), the United Kingdom (UK), France, Germany, and Japan were extracted from their packet inserts. Results A significant proportion of “atypical antipsychotics” were approved for psychiatric conditions other than psychotic disorders (i. e., bipolar disorder, major depressive disorder, and autistic disorder) as follows: 76.9% in the US, 66.7% in the UK, 66.7% in France, 60.0% in Germany, and 44.4% in Japan. Likewise, more than half of “newer antidepressants” had approved indications for psychiatric conditions other than depression (e. g., panic disorder, obsessive compulsive disorder, social anxiety disorder, general anxiety disorder, and post-traumatic stress disorder): 56.3% in the US, 69.2% in the UK, 69.2% in France, 50.0% in Germany, and 62.5% in Japan. Conclusions Our results raise concerns regarding generic terminologies of “antipsychotics” and “antidepressants” since the conventional indication-based nomenclature does not fit well with the official indication.

AB - Introduction While the current nomenclature of psychotropic drugs is disease-based, their approved indications do not always match their classifications. Methods Information on approved indications of “second-generation antipsychotics” and “newer antidepressants” that are available in the United States (US), the United Kingdom (UK), France, Germany, and Japan were extracted from their packet inserts. Results A significant proportion of “atypical antipsychotics” were approved for psychiatric conditions other than psychotic disorders (i. e., bipolar disorder, major depressive disorder, and autistic disorder) as follows: 76.9% in the US, 66.7% in the UK, 66.7% in France, 60.0% in Germany, and 44.4% in Japan. Likewise, more than half of “newer antidepressants” had approved indications for psychiatric conditions other than depression (e. g., panic disorder, obsessive compulsive disorder, social anxiety disorder, general anxiety disorder, and post-traumatic stress disorder): 56.3% in the US, 69.2% in the UK, 69.2% in France, 50.0% in Germany, and 62.5% in Japan. Conclusions Our results raise concerns regarding generic terminologies of “antipsychotics” and “antidepressants” since the conventional indication-based nomenclature does not fit well with the official indication.

KW - antidepressant

KW - antipsychotic

KW - indication

KW - NbN

KW - neuroscience-based nomenclature

UR - http://www.scopus.com/inward/record.url?scp=85047338634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047338634&partnerID=8YFLogxK

U2 - 10.1055/a-0626-7135

DO - 10.1055/a-0626-7135

M3 - Article

C2 - 29791934

AN - SCOPUS:85047338634

JO - Pharmacopsychiatry

JF - Pharmacopsychiatry

SN - 0176-3679

ER -